CLINICAL OBSERVATIONS ON A NEW PROGESTATIONAL AGENT, »ALLYLESTRENOL«

Abstract

ABSTRACT 1. A new steroid, 17α-allyl-17β-hydroxy-estr-4-ene (allylestrenol) is an orally effective progestational compound. 2. Forty-three female patients received 71 courses of allylestrenol. Withdrawal bleeding occurred in 59 instances, with as low a total dosage as 50 to 75 mg over a period of five days. 3. In five of the eleven patients a thermogenic response was noted. 4. Thirty to forty milligrams of allylestrenol with 0.12 to 0.2 mg of ethinyl oestradiol-3-methyl ether successfully delayed menses when administered for 20 days starting 6 to 7 days after ovulation. 5. Allylestrenol with an oestrogen induced progestational changes in a castrated female. 6. Allylestrenol did not suppress adrenal function in 2 patients with congenital adrenal hyperplasia but did appear to have some anti-oestrogenic effects in the treatment of two children with sexual precocity. 7. Allylestrenol is a pure and safe progestational agent without apparent androgenic, oestrogenic, or other side effects.